Latest updates for Amgn
Fresh curated links around amgn are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Amgen Inc. (AMGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
- Argenx
Post angles to try
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
Amgen vs. Axsome Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Amgen generated $8.1 billion in free cash flow in 2025, with a 21% net margin, while Axsome is scaling rapidly but still unprofitable.
Argenx
Argenx Anonymous (not verified) Mon, 10/19/2026 - 10:14 field_thread_url https://cafepharma.com/boards/threads/argenx.665212/ board name...
Amgen: Why Rivals' Cholesterol Drug Fail Is Bad News For The Pharma (Rating Downgrade)
Amgen vs. Eli Lilly: Does the GLP-1 Mania Make LLY Stock a Better Buy in 2026?
Amgen trades at half the valuation multiple of Eli Lilly while generating stronger free cash flow, but explosive growth in obesity drugs tells a different story.
ANC
ANC Anonymous (not verified) Mon, 09/14/2026 - 18:53 field_thread_url https://cafepharma.com/boards/threads/anc.712901/ board name...
2 Dividend Stocks Crushing the Market in 2026 (and Which Ones Can Keep Going)
These drugmakers are facing some near-term challenges, but is that enough to stop their recent momentum?
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.